The increased activation of the PAM pathway is also involved in the development of resistance to drugs used to treat patients with BC, such as endocrine therapy (ET) and CDK4/6 inhibitors, which are the standard of care for patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC). This evidence concerns the gene ERBB2 and breast carcinoma.